Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 | P31639 | 20/20 | 0.41 |
| ▸ | SLC5A1 | P13866 | 15/20 | 0.41 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.38 |
| ▸ | SLC5A11 | Q8WWX8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14215765 | 0.86 | SLC5A2 (0.35) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL12956970 | 0.78 | SLC5A2 (0.39) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL12965051 | 0.78 | SLC5A2 (0.50) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL882697 | 0.75 | SLC5A2 (0.37) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL12797197 | 0.74 | SLC5A2 (0.39) | SLC5A2SLC5A1 | |
| SCHEMBL14215830 | 0.74 | SLC5A2 (0.35) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL10328445 | 0.74 | SLC5A1 (0.51) | SLC5A2SLC5A1 | |
| SCHEMBL10292573 | 0.74 | SLC5A1 (0.51) | SLC5A2SLC5A1 | |
| SCHEMBL1036645 | 0.67 | SLC5A2 (0.68) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL1037836 | 0.67 | SLC5A2 (0.68) | SLC5A2SLC5A1ADRA2ASLC5A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100311673-A1 | SULFANYL-TETRAHYDROPYRAN-BASED COMPOUNDS AND METHODS OF THEIR USE | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2010-12-09 | — | — | US | disclosed |
| US-7846945-B2 | Piperdine-based inhibitors of sodium glucose co-transporter 2 and methods of their use | LEXICON PHARMACEUTICALS, INC. (US) | 2010-12-07 | — | — | US | disclosed |
| US-7781577-B2 | 2-[4-Chloro-3-(4-hydroxy-benzyl)-phenyl]-6-methoxy-tetrahydro-pyran-3,4,5-triol; 2-[4-Chloro-3-(4-ethoxy-benzyl)-phenyl]-3,4,5-trihydroxy-piperidine-1-carboxylic acid methyl ester; (2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-methoxytetrahydro-2H-thiopyran-3,4,5-triol; antidibetic, antiobesity agents | LEXICON PHARMACEUTICALS, INC. (US) | 2010-08-24 | — | — | US | disclosed |
| US-20080221164-A1 | Inhibitors of Sodium Glucose Co-Transporter 2 and Methods of Their Use | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2008-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311673-A1 | SULFANYL-TETRAHYDROPYRAN-BASED COMPOUNDS AND METHODS OF THEIR USE | GPR119, FABP4, LIPC | SLC5A2 16/4885SLC5A1 48/4885ADRA2A 1576/4885 |
| US-20080221164-A1 | Inhibitors of Sodium Glucose Co-Transporter 2 and Methods of Their Use | SLC2A1, SLC2A2, SLC5A2 | SLC5A2 3/4885SLC5A1 8/4885ADRA2A 831/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.